148 related articles for article (PubMed ID: 7913894)
1. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Hauber W; Waldenmeier MT
Eur J Pharmacol; 1994 May; 256(3):339-42. PubMed ID: 7913894
[TBL] [Abstract][Full Text] [Related]
2. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
Tzschentke TM; Schmidt WJ
Eur J Pharmacol; 1996 Jan; 295(2-3):137-46. PubMed ID: 8720577
[TBL] [Abstract][Full Text] [Related]
3. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
4. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
[TBL] [Abstract][Full Text] [Related]
5. The depressant effect of GYKI 52466 on spinal reflex transmission in rats is mediated via non-NMDA and benzodiazepine receptors.
Block F; Schwarz M
Eur J Pharmacol; 1994 Apr; 256(2):149-53. PubMed ID: 8050465
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with NMDA antagonist, CGP 37849, and sigma receptor agonists, SA4503 or DTG, decreases the neuroleptic-induced catalepsy in rats.
Skuza G
Pol J Pharmacol; 2000; 52(4):313-6. PubMed ID: 11345488
[TBL] [Abstract][Full Text] [Related]
7. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Zadow B; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
[TBL] [Abstract][Full Text] [Related]
8. Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity.
Maj J; Skuza G; Rogóz Z
J Neural Transm Park Dis Dement Sect; 1993; 6(1):53-62. PubMed ID: 8105798
[TBL] [Abstract][Full Text] [Related]
9. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
Donevan SD; Yamaguchi S; Rogawski MA
J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
[TBL] [Abstract][Full Text] [Related]
10. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.
Bubser M; Tzschentke T; Hauber W
J Neural Transm Gen Sect; 1995; 101(1-3):115-26. PubMed ID: 8695042
[TBL] [Abstract][Full Text] [Related]
11. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Riedinger K; Kulak A; Schmidt WJ; von Ameln-Mayerhofer A
Behav Brain Res; 2011 Mar; 218(1):194-9. PubMed ID: 21130808
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of adenosine A2a receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-D-aspartate receptors.
Hauber W; Münkle M
Neurosci Lett; 1995 Aug; 196(3):205-8. PubMed ID: 7501284
[TBL] [Abstract][Full Text] [Related]
13. The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin1A receptors.
Löscher W; Hönack D
J Pharmacol Exp Ther; 1991 Jun; 257(3):1146-53. PubMed ID: 1675288
[TBL] [Abstract][Full Text] [Related]
14. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures.
Dürmüller N; Craggs M; Meldrum BS
Epilepsy Res; 1994 Feb; 17(2):167-74. PubMed ID: 8194512
[TBL] [Abstract][Full Text] [Related]
15. Anticonvulsant effects of eliprodil alone or combined with the glycineB receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats.
Wlaź P; Ebert U; Löscher W
Neuropharmacology; 1999 Feb; 38(2):243-51. PubMed ID: 10218865
[TBL] [Abstract][Full Text] [Related]
16. Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats.
Löscher W; Hönack D
Eur J Pharmacol; 1993 Apr; 234(2-3):237-45. PubMed ID: 8097722
[TBL] [Abstract][Full Text] [Related]
17. Riluzole, a glutamate release inhibitor, and motor behavior.
Kretschmer BD; Kratzer U; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):181-90. PubMed ID: 9750003
[TBL] [Abstract][Full Text] [Related]
18. Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia.
Nellgård B; Wieloch T
J Cereb Blood Flow Metab; 1992 Jan; 12(1):2-11. PubMed ID: 1345757
[TBL] [Abstract][Full Text] [Related]
19. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.
Kretschmer BD; Zadow B; Volz TL; Volz L; Schmidt WJ
J Neural Transm Gen Sect; 1992; 87(1):23-35. PubMed ID: 1346965
[TBL] [Abstract][Full Text] [Related]
20. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity.
Fagg GE; Olpe HR; Pozza MF; Baud J; Steinmann M; Schmutz M; Portet C; Baumann P; Thedinga K; Bittiger H
Br J Pharmacol; 1990 Apr; 99(4):791-7. PubMed ID: 1972895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
